ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN

<p>Thiazides are recommended first line agents for the treatment of hypertension.  They have been demonstrated to lower cardiovascular disease.  Which thiazide to choose has been a long-standing issue.</p> <p>In this interview, Areef Ishani MD, MS and W. Douglas Weaver MD, MACC discuss AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension.</p> <p><a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046"> Subscribe on Apple</a> Podcasts | <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq"> Subscribe on Google Play</a> | <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio"> Subscribe to ACCEL</a></p>